Below are the most recent publications written about "Peroxisome Proliferator-Activated Receptors" by people in Profiles.
-
Borland MG, Yao PL, Kehres EM, Lee C, Pritzlaff AM, Ola E, Wagner AL, Shannon BE, Albrecht PP, Zhu B, Kang BH, Robertson GP, Gonzalez FJ, Peters JM. Editor's Highlight: PPAR?/d and PPAR? Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis. Toxicol Sci. 2017 10 01; 159(2):436-448.
-
Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012 Feb 09; 12(3):181-95.
-
Peters JM, Gonzalez FJ. Why toxic equivalency factors are not suitable for perfluoroalkyl chemicals. Chem Res Toxicol. 2011 Oct 17; 24(10):1601-9.
-
Palkar PS, Borland MG, Naruhn S, Ferry CH, Lee C, Sk UH, Sharma AK, Amin S, Murray IA, Anderson CR, Perdew GH, Gonzalez FJ, M?ller R, Peters JM. Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol. 2010 Sep; 78(3):419-30.
-
Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A. Peroxisome proliferator-activated receptors and angiogenesis. Nutr Metab Cardiovasc Dis. 2009 Dec; 19(11):751-9.
-
Roman J. Moving away from PPARs - EGFR signaling and the anti-cancer effects of thiazolinedinediones. Cell Res. 2009 Jun; 19(6):669-71.
-
Gopinathan L, Hannon DB, Peters JM, Vanden Heuvel JP. Regulation of peroxisome proliferator-activated receptor-alpha by MDM2. Toxicol Sci. 2009 Mar; 108(1):48-58.
-
Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci. 2006 Apr; 90(2):269-95.
-
Bility MT, Thompson JT, McKee RH, David RM, Butala JH, Vanden Heuvel JP, Peters JM. Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol Sci. 2004 Nov; 82(1):170-82.